The structure-function relationship of hereditary dysfibrinogens

International Journal of Hematology

Volumn 64, Issue 3-4, 1996, Pages 167-179

  Matsuda, Michio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Amino acid substitution; Domain structure of fibrinogen; Fibrin polymerization; Fibrin protofibrils; Hereditary dysfibrinogen

Indexed keywords

DYSFIBRINOGEN; FIBRIN; FIBRINOGEN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; DYSFIBRINOGENEMIA; HUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0030273580     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/0925-5710(96)00482-3     Document Type: Review

References (83)

1. [1] Doolittle RF, Bouma III H, Cottrell BA, Strong D, Watt KWK. The covalent structure of human fibrinogen. In: Bing DH. (ed). The Chemistry and Physiology of the Human Plasma Proteins. New York: Pergamon Press, 1979;77-95.
2. [2] Furlan M. Structure of fibrinogen and fibrin. In: Francis JL. (ed). Fibrinogen, Fibrin Stabilisation, and Fibrinolysis. Chichester: Ellis Horwood, 1988;17-64.
3. [3] Doolittle RF. Fibrinogen and fibrin. In: Bloom AL and Thomas DP. (eds). Haemostasis and Thrombosis, 2nd Edn. Edinburgh: Churchill Livingstone, 1981;163-191.
4. [4] Ebert RF. (ed). Index of Variant Human Fibrinogens. Boca Raton (Florida): CRC Press, 1991.
5. [5] Koopman J, Haverkate F. Hereditary variants of human fibrinogens. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. (eds). Haemostasis and Thrombosis, 3rd Edn. Edinburgh: Churchill Livingstone, 1994;515-529.
6. [6] Blombäck M, Blombäck B, Mammen EF, Prasad AS. Fibrinogen 'Detroit': a molecular defect in the N-terminal disulphide knot of human fibrinogen. Nature 1968;218:134-137.
7. [7] Mammen EF, Prasad AS, Barnhart MI, Au CC. Congenital dysfibrinogenemia fibrinogen Detroit. J Clin Invest 1969;48:235-249.
8. 2-terminal polymerisation domain. Thromb Res 1976;9:25-36.
9. [9] Kudryk BJ, Collen D, Woods KR, Blombäck B. Evidence for localization of polymerization sites in fibrinogen. J Biol Chem 1974;249:3322-3325.
10. [10] Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci USA 1980;77:1374-1378.
11. [11] Laudano AP, Doolittle RF. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences. Biochemistry 1980;19:1013-1019.
12. [12] Olexa S, Budzynski AZ. Localization of a fibrin polymerization site. J Biol Chem 1981;256:3544-3549.
13. [13] Horwitz BH, Váradi A, Scheraga HA. Localization of a fibrin γ-chain polymerization site within segment Thr-374 to Glu-396 of human fibrinogen. Proc Natl Acad Sci USA 1984;81:5980-5984.
14. [14] Cierniewski CS, Budzynski AZ. Localization of the cross-linking site of GPRVVERHK in the γ-chain of human fibrinogen. Eur J Biochem 1993;218:321-325.
15. [15] Kehl M, Lottspeich F, Henschen A. Analysis of human fibrinopeptides by high-performance liquid chromatography. Hoppe-Seyler's Z Physiol Chem 1981;362:1661-1664.
16. [16] Higgins DL, Shafer JA. Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-Aα 16 by a histydyl residue. Evidence for thrombin-catalyzed hydrolysis at a histidyl residue. J Biol Chem 1981;256:12013-12017.
17. [17] Henschen A, Kehl M, Southan S. Genetically abnormal fibrinogens - strategies for structure elucidation, including fibrinopeptide analysis. In: Beck EA, Furlan M. (eds). Variants of Human Fibrinogen. Bern: Hans Huber Verlag, 1984;273-320.
18. [18] Matsuda M. Molecular abnormalities of fibrinogen -the present status of structure elucidation. In: Matsuda M, Iwanaga S, Takada A, Henschen A. (eds). Fibrinogen 4. Current Basis and Clinical Aspects. Amsterdam: Excerpta Medica, 1990;139-152.
19. [19] Martin PD, Robertson W, Turk D, Huber R, Bode W, Edward BFP. The structure of residues 7-16 of the Aα-chain of human fibrinogen bound to bovine thrombin at 2.3-Å resolution. J Biol Chem 1992;267:7911-7920.
20. [20] Stubb MT, Aschkinat H, Mayr I et al. The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur J Biochem 1992;206:187-195.
21. [21] Niwa K, Yaginuma A, Nakanishi M et al. Fibrinogen Mitaka II: a hereditary dysfibrinogen with defective thrombin binding caused by an Aα Glu-11 to Gly substitution. Blood 1993;82:3658-3663.
22. [22] Southan C. The elucidation of molecular defects in congenital dysfibrinogenemia. In: Francis JL. (ed). Fibrinogen, Fibrin Stabilisation, and Fibrinolysis. Chichester: Ellis Horwood, 1988;100-127.
23. [23] Zheng Z, Ashton RW, Ni F, Scheraga HA. Thrombin hydrolysis of an N-terminal peptide from fibrinogen Lille: kinetic and NMR studies. Biochemistry 1992;31:4426-4431.
24. [24] Wada Y, Niwa K, Maekawa H et al. A new type of congenital dysfibrinogen, fibrinogen Bremen, with an Aα Gly-17 to Val substitution associated with hemorrhagic diathesis and delayed wound healing. Thromb Haemost 1993;70:397-403.
25. [25] Yamazumi K, Doolittle RF. Photoaffinity labeling of the primary fibrin polymerization site: localization of the label to γ-chain Tyr-363. Proc Natl Acad Sci USA 1992;89:2893-2896.
26. [26] Yamazumi K, Shimura K, Terukina S, Takahashi N, Matsuda M. A γ methionine-310 to threonine substitution and consequent N-glycosylation at γ asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi. J Clin Invest 1989;83:1590-1597.
27. [27] Matsuda M, Baba M, Morimoto K, Nakamikawa C. Fibrinogen Tokyo II. An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules. J Clin Invest 1983;72:1034-1041.
28. [28] Mosesson MW, Siebenlist KR, Hainfeld JF, Wall JS. The covalent structure of factor XIIIa crosslinked fibrinogen fibrils. J Struct Biol 1995;115:88-101.
29. [29] Mosesson MW, Siebenlist KR, DiOlio JP, Matsuda M, Hainfeld JF, Wall JS. The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (γ275Arg→Cys). J Clin Invest 1995;96:1053-1058.
30. [30] Niwa K, Takebe M, Sugo T et al. A γGly-268 to Glu substitution is responsible for impaired fibrin assembly in a homozygous dysfibrinogen Kurashiki I. Blood 1996;87:4686-4694.
31. [31] Hantgan R, Fowler W, Erickson H, Hermans J. Fibrin assembly: a comparison of electron microscopic and light scattering results. Thromb Haemost 1980;44:119-124.
32. [32] Mosesson MW, DiOlio JP, Siebenlist KR, Wall JS, Hainfeld JF. Evidence for a second type of fibril branch point in fibrin polymer networks, the trimolecular junction. Blood 1993;82:1517-1521.
33. [33] Weisel JW, Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with elctron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 1992;63:111-128.
34. [34] Veklich YI, Gorkun OV, Medved LV, Nieuwenhuizen W, Weisel JW. Carboxyl-terminal portions of the α chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated αC fragments on polymerization. J Biol Chem 1993;268:13577-13585.
35. [35] Blombäck B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 1978;275:501-505.
36. [36] Maekawa H, Yamazumi K, Muramatsu S et al. An Aα Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation. J Biol Chem 1991;266:11575-11581.
37. [37] Maekawa H, Yamazumi K. Muramatsu S et al. Fibrinogen Lima: a homozygous dysfibrinogen with an Aα-arginine-141 to serine substitution associated with extra N-glycosylation at Aα-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator. J Clin Invest 1992;90:67-76.
38. [38] Suenson E, Bjerrum P, Holm A et al. The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation. J Biol Chem 1990;265:22228-22237.
39. [39] Langer BG, Weisel JW, Dinauer PA, Nagaswami C, Bell NR. Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers. J Biol Chem 1988;263:15056-15063.
40. [40] Galanakis D, Martinez J, Mc Devitt C, Miller F. Human fetal fibrinogen: its characteristics of delayed fibrin formation, high sialic acid and AP peptide content are more marked in pre-term than in term samples. Ann NY Acad Sci 1983;408:640-643.
41. [41] Terch RR, Trolp R, Witt I. Electron microscopic studies on the fetal fibrin clot. Thromb Res 1979;16:239-243.
42. [42] Martinez J, Paloscak JE, Peters C. Functional and metabolic properties of human asialofibrinogen. J Lab Clin Med 1977;89:367-377.
43. [43] Woodhead JL, Nagaswami C, Matsuda M, Arocha-Piñango CL, Weisel JW. The ultrastructure of fibrinogen Caracas II molecules, fibers and clots. J Biol Chem (in press).
44. [44] Margucrie G, Chagniel G, Suscillion M. The binding of calcium to bovine fibrinogen. Biochim Biophys Acta 1977;490:94-103.
45. [45] Haverkate F, Timan G. Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragments. Thromb Res 1977;10:803-812.
46. [46] Fowler WE, Erickson HP. Trinodular structure of fibrinogen. Confirmation by both shadowing and negative stain electron microscopy. J Mol Biol 1979;134:241-249.
47. [47] Dang CV, Ebert RF. Bell WR. Localization of a fibrinogen calcium binding site between γ-subunit positions 311 and 336 by terbium fluorescence. J Biol Chem 1985;260:9713-9719.
48. [48] Liu CY, Nossel HL, Kaplan KL. The binding of thrombin to fibrin. J Biol Chem 1979;254:10421-10425.
49. [49] Havarkate F, Koopman J, Kluft C, D'Angelo A. Cattaneo M, Mannucci PM. Fibrinogen Milano II: a congenital dysfibrinogenemia associated with juvenile arterial and venous thrombosis. Thromb Haemost 1986;55:131-135.
50. [50] Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982;257:2920-2925.
51. [51] Nieuwenhuizen W, Vermond A, Voskuilen M, Traas DW, Verheijen JH. Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator. Biochim Biophys Acta 1983;748:86-92.
52. [52] Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983;258:4249-4256.
53. [53] Váradi A, Patthy L. Location of plasminogen binding sites in tibrin(ogen). Biochemistry 1983;22:2440-2446.
54. [54] Hawiger J, Timmons S, Kloczewiak M, Strong DD, Doolittle RF. Gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors. Proc Natl Acad Sci USA 1982;79:2068-2071.
55. [55] Strong DD, Laudano AP, Hawiger J, Doolittle RF. Isolation, characterization, and synthesis of peptides from human fibrinogen that black the staphylococcal clumping reaction and construction of a synthetic clumping principle. Biochemistry 1982;21:1414-1420.
56. [56] Dejana E, Languino LR, Polentarutti N et al. Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J Clin Invest 1985;75:11-18.
57. [57] Gonda SR, Shainoff JR. Adsorptive endocytosis of fibrin monomer by macrophages: evidence of a receptor for the amino terminus of the fibrin α chain. Proc Natl Acad Sci USA 1982;79:4565-4569.
58. [58] Koopman J, Haverkate F, Briet E, Lord ST. A congenitally abnormal fibrinogen (Vlissingen) with a 6-base deletion in the γ-chain gene, causing defective calcium binding and impaired fibrin polymerization. J Biol Chem 1991;266:13456-13461.
59. [59] Steinmann C, Reber P, Jungo M et al. Fibrinogen Bern I: substitution of γ 337 Asn → Lys is responsible for defective fibrin monomer polymerization. Blood 1993;82:2104-2108.
60. [60] Yoshida N, Hirata H, Morigami Y et al. Characterization of an abnormal fibrinogen Osaka V with the replacement of γ-arginine 375 by glycine. J Biol Chem 1992;267:2753-2759.
61. [61] Liu CY, Koehn JA, Morgan FJ. Characterization of fibrinogen New York I. A dysfunctional fibrinogen with a deletion of Bβ (9-72) corresponding exactly to exon 2 of the gene. J Biol Chem 1985;260:4390-4396.
62. [62] Koopman J, Haverkate F, Lord ST, Grimbergen J, Mannucci PM. Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of Bβ 68 Ala →Thr. J Clin Invest 1992;90:238-244.
63. [63] Voskuilen M, Vermond A, Veeneman GH et al. Fibrinogen lysine residue Aα 157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, catalyzed by tissue-type plasminogen activator. J Biol Chem 1987;262:5944-5946.
64. [64] Yonekawa O, Voskuilen M, Nieuwenhuizen W. Localization in the fibrinogen γ-chain of a new site that is involved in the acceleration of the tissue-type plasminogen activator-catalyzed activation of plasminogen. Biochem J 1992;283:187-191.
65. [65] Hoylaerts M, Rijken DJ, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982;257:2912-2919.
66. [66] Soria J. Soria C, Caen JP. A new type of congenital dysfibrinogenemia with defective fibrin lysis - Dusard syndrome: possible relation to thrombosis. Br J Haematol 1983;53:575-586.
67. [67] Carrell N, Gabriel DA, Blatt PM, Carr ME, McDonagh J. Hereditary dysfibrinogenemia in a patient with thrombotic disease. Blood 1983;62:439-447.
68. [68] Koopman J, Haverkate F, Grimbergen J et al. Molecular basis for fibrinogen Dusart (Aα 554 Arg → Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 1993;91:1637-1643.
69. [69] Wada Y, Lord ST. A correlation between thrombotic disease and a specific fibrinogen abnormality (Aα 554 Arg → Cys) in two unrelated kindred. Dusart and Chapel Hill III. Blood 1994;84:3709-3714.
70. [70] Collet JP, Woodhead JL, Soria J et al. Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots. Biophys J 1996;70:500-510.
71. [71] Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids Aα 461-610 (Lys 461 AAA → Stop TAA). Blood 1992;80:1972-1979.
72. [72] Lorand L, Konishi K, Jacobsen A. Transpeptidation mechanism in blood clotting. Nature 1962;194:1148-1149.
73. [73] Chen R, Doolittle RF. γ-γ cross-linking site in human and bovine fibrin. Biochemistry 1971;10:4486-4491.
74. [74] Budzynski AZ, Marder VJ, Ménaché D, Guillin M-C. Defect in the gamma polypeptide chain of a congenital abnormal fibrinogen (Paris I). Nature 1974;252:66-68.
75. [75] Rosenberg JB, Newman PJ, Mosesson MW, Guillin M-C, Amrani DL. Paris I dysfibrinogenemia: a point mutation in intron 8 results in insertion of a 15 amino acid sequence in the fibrinogen γ-chain. Thromb Haemost 1993;69:217-220.
76. [76] Cottrell BA, Strong DD, Watt KW, Doolittle RF. Amino acid sequence studies on the α-chain of human fibrinogen. Exact location of cross-linking acceptor sites. Biochemistry 1979;18:5405-5410.
77. [77] Corcoran BA, Ferguson EW, Fretto LJ, McKee PA. Localization of a cross-link donor site in the α-chain of human fibrin. Thromb Res 1980:19:883-888.
78. [78] Townsend RR, Hilliker RE, Li Y-T, Laine RA, Bell WR, Lee YC. Carbohydrate structure of human fibrinogen. J Biol Chem 1982;257:9704-9710.
79. [79] Kaudewitz H, Menschen A, Soria J, Soria C. Fibrinogen Pontoise - a genetically abnormal fibrinogen with defective fibrin polymerization but normal fibrinopeptide release. In: Lane DA, Henschen A, Jasani MK. (eds). Fibrinogen, Fibrin Formation and Fibrinolysis. Berlin: Walter du Gruyter 1986;91-96.
80. [80] Miyata T, Terukina S. Matsuda M et al. Fibrinogens Kawaguchi and Osaka: an amino acid substitution of Aα arginine-16 to cysteine which forms an extra interchain disulfide bridge between the two Aα chains. J Biochem (Tokyo) 1987;102:93-101.
81. [81] Koopman J, Haverkate F, Grimbergen J et al. Abnormal fibrinogens Umuiden (Bβ Arg 14 → Cys) and Nijmegen (Bβ Arg 44 → Cys) form disulfide-linked fibrinogen-albumin complexes. Proc Natl Acad Sci USA 1992;89:3478-3482.
82. [82] Kamura T, Tsuda H, Yae Y et al. An abnormal fibrinogen Fukuoka II (Gly-Bβ 15 → Cys) characterized by defective fibrin lateral association and mixed disulfide formation. J Biol Chem 1995;270:29392-29399.
83. [83] Terukina S, Matsuda M, Hirata H et al. Substitution of γ Arg-275 by Cys in an abnormal fibrinogen, 'fibrinogen Osaka II'. Evidence for a unique solitary cystine structure at the mutation site. J Biol Chem 1988;263:13579-13587.